Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Defeating Breast Cancer Through Crowdsourcing -- Please Donate Your Mammograms to Help Defeat Breast Cancer
  • USA - English


News provided by

www.YourScan.org

Aug 20, 2015, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Lesion Tissue Profile
Lesion Tissue Profile

spots early Breast Cancer not visible to the eye in mammograms; identifies benign from malignant tumors

Post this

San Francisco, CA (PRWEB) August 20, 2015 -- In a pilot test conducted over the last three years, YourScan.org has shown that its Lesion Tissue Profiling technology is capable of accurately detecting the shapes of malignant tumors (lesions) otherwise not visible to the human eye. The study further indicated that these lesions have a limited number of basic shapes that can be rendered as distinct tissue profiles common to all malignancy. The implication is that these profiles may be used as a tool in routine screening of all mammography. This could present an important breakthrough – the first automated digital search of the more than 30 million mammograms done in the US each year, a search that would offer valuable diagnostic insight.

     The company, YourScan.org, has built a proprietary database specifically designed to store mammographic images in a format allowing for rapid and precise comparison of billions of tissue profiles. The data is highlighted using a visual-based color illustrator and the technology catalogues each shape – assembling a “tissue profile” that can be matched with other tissue profiles. Searching “healthy” mammograms using those tissue profiles has revealed that the technology can detect “precursor” tissue profiles in digital mammograms, both two-dimensional and newer 3-D images produced by tomosynthesis technology.

     The Company is asking women diagnosed with breast cancer to provide their entire series of mammograms to compare earlier mammograms to the later one that resulted in a definitive diagnosis; identifying and cataloging precursor and lesion tissue profiles found in their mammograms. These newly identified tissue profiles will be added to the tissue profile library, and used to search other mammograms for breast cancer precursors and lesions.

     The YourScan.org research to date offers a tantalizing possibility. There appears to be a finite number of distinct tissue profiles to be assembled into a large library. Once assembled, mammograms can be rapidly searched against this library, looking for matching precursor and lesion tissue profiles. In pilot tests, such matches proved to be 99.9 percent accurate, conclusively detecting cancer or eliminating false positives. The hope is that the technology could become an invaluable routine tool for radiologists. It could be used as a universal “double-check” based on the growing national library of identified tissue profiles, resulting in early detection of not-readily-visible precursors as well as distinguishing benign from malignant lesions.

                                                     Crowdsourcing – Big Data is Critical

     This potential can only be reached, however, if the library is comprehensive. Conventional clinical trials and medical research studies typically analyze data from a couple hundred to a few thousand patients. Larger studies that compare findings of multiple studies do not assemble large collections of individual images. That is why the Company has turned to crowdsourcing. If some of the millions of women across America stricken with this disease were to donate their mammograms, a complete library of tissue profiles could be quickly assembled. As the database grew, its utility and accuracy would increase geometrically. The Company’s technology resides in the Amazon Cloud and is scalable for millions of concurrent searches and mammograms.

     Accordingly, http://www.YourScan.org seeks donated mammograms with physician-diagnosed lesion(s) of any type. To donate a mammogram, please go to the website and fill out a release form for your mammogram sets and they will formally request a copy of them from your doctor. If you already have copies, you can directly upload them from the website http://www.YourScan.org.

     The crowd-sourcing approach seeks to accelerate the data collection and assemble the comprehensive library. The universal application of the scanning technology for diagnostic purposes will require collaboration with medical institutional partners and ultimately federal regulatory review and approval.

                                     How Does it Work? – The Leaves of a Maple Tree

     Compared with existing image recognition software, the YourScan.com website uses an entirely different technology: Ldb3 technology. The standard approach is to mechanically count pixels and make numerical comparisons that are often useful but sometimes misleading, especially when dealing with organic shapes such as lesions.

     By contrast, Ldb3 technology mimics the process of human vision. Like the leaves of a maple tree, no two lesions are identical. Yet when shown a maple leaf, we can identify it as belonging to a maple tree because it “looks like a maple leaf.” We do this by visually generalizing a leaf's specific features and engaging in what digital recognition technologists call “visual rounding.” It is a kind of pattern or shape recognition based on previous identifications. This is the same process used by Ldb3 technology and is remarkably fast and accurate. Using the tissue profile library it identifies tissue patterns missed by the human eye or not recognized by other technologies.

     The attached image is Ldb3 tissue profiled malignant lesion that illustrates the technology, using a 2-D mammogram. The technology detects and highlights the tissue patterns isolating them in green, against the gray and white background of the mammogram. Seen this way, lesions clearly have distinct shapes that, while not identical, share distinct characteristic features.

     Mammograms can be scanned against the library of known precursor and lesion tissue profiles. On the http://www.YourScan.org website is a screen shot of the technology doing such a scan. And, a mammogram you can perform a scan with looking for malignant lesions, using earlier recorded lesion tissue profiles.

     As the tissue profile library expands with additional donated mammograms, the statistical significance of its analysis will sharpen even further. The tissue profiling of a first 2,000 lesions has yielded some tantalizing preliminary results. In the examples on their website, http://www.YourScan.org the Ldb3 technology appears to distinguish a benign lesion from a malignant lesion. It does this by revealing the existence of a central core in the malignant lesion. Recognizing this tissue pattern has proven to be a reliable method to distinguish between benign and malignant lesions. That is, malignant lesions appear to have a centralized core that the mass grows outward from, whereas benign lesions appear to lack such a core. The http://www.YourScan.org website has diagnosed benign and malignant examples that clearly show the difference in their tissue profiling.

     Moreover, mammographic images of the same two lesions without the Ldb3 technology highlighting. As is readily apparent from the website images, it is virtually impossible for the human eye to detect the lesion. Only with Ldb3 highlighting is either one readily visible on the website.

Kenneth Boulange, www.YourScan.org, http://www.YourScan.org, +1 415 987 9414, [email protected]

Modal title

Press Release
View PDF
Press Release
Press Release

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.